Zobrazeno 1 - 10
of 73
pro vyhledávání: '"YiMing Weng"'
Autor:
Yiming Weng, Jingping Yuan, Xue Cui, Jinsong Wang, Honglei Chen, Li Xu, Xinyi Chen, Min Peng, Qibin Song
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-16 (2024)
Abstract Non-small cell lung cancer (NSCLC) is a common malignancy whose prognosis and treatment outcome are influenced by many factors. Some studies have found that tertiary lymphoid structures (TLSs) in cancer may contribute to prognosis and the pr
Externí odkaz:
https://doaj.org/article/25ab8d2c3ecd4f97acc3a72287df633d
Autor:
Jia Feng, Xinyi Chen, Jiayan Wei, Yiming Weng, Jingsong Wang, Tong Wang, Qibin Song, Peng Min
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract We conducted a retrospective study to evaluate the efficacy of immune checkpoint inhibitor (ICI) rechallenge in patients with advanced non-small cell lung cancer (NSCLC). The study included 111 patients who had previously received ICI therap
Externí odkaz:
https://doaj.org/article/c46efb15e2814d159199f99c94853606
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Tumor-associated high endothelial venules (TA-HEVs) mediate lymphocyte entry into tumors. Therefore, combined anti-angiogenesis therapy and programmed death-1 (PD-1) inhibitors might stimulate tumor immunity. This study will explore the TA-H
Externí odkaz:
https://doaj.org/article/c4569b9f4c6f4b1bb675bfeb8d482a63
Publikováno v:
BMC Bioinformatics, Vol 24, Iss 1, Pp 1-21 (2023)
Abstract Lung squamous cell carcinoma (LUSC) is associated with a worse prognosis than other histological subtypes of non-small cell lung cancer. Due to the vital role of CD8+ T cells in anti-tumor immunity, the characterization of CD8+ T cell infilt
Externí odkaz:
https://doaj.org/article/2ee8a1a2937c4395b4f28fde1bf28125
Autor:
Jinsong Wang, Xue Cui, Yiming Weng, Jiayan Wei, Xinyi Chen, Peiwei Wang, Tong Wang, Jian Qin, Min Peng
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
Lung adenocarcinoma (LUAD) is an essential pathological subtype of non-small cell lung cancer and offers a severe problem for worldwide public health. There is mounting proof that angiogenesis is a crucial player in LUAD progression. Consequently, th
Externí odkaz:
https://doaj.org/article/7a692741945440a8868055be3c25b7a0
Publikováno v:
Cell Transplantation, Vol 31 (2022)
Accumulating data show that N6-methyladenosine (m 6 A) methyltransferase METTL3 and long noncoding RNA MALAT1 act pivotal roles in multiple malignancies including prostate cancer (PCa). However, the role and molecular mechanism underlying METTL3-medi
Externí odkaz:
https://doaj.org/article/f720cc11bd1f45638586808132250346
Autor:
Yao Jin, Jiayan Wei, Yiming Weng, Jia Feng, Zexi Xu, Peiwei Wang, Xue Cui, Xinyi Chen, Jinsong Wang, Min Peng
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundImmune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment of patients with advanced tumors. However, little is known about their efficacy and safety in adjuvant settings after the resection of solid tumors.Metho
Externí odkaz:
https://doaj.org/article/6d61ee7fa95443eabca649f3112ab6dc
Autor:
Jiayan Wei, Jia Feng, Yiming Weng, Zexi Xu, Yao Jin, Peiwei Wang, Xue Cui, Peng Ruan, Ruijun Luo, Na Li, Min Peng
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundCirculating tumor DNA (ctDNA) levels and blood tumor mutation burden (bTMB) have a significant impact on the prognosis of tumor patients. However, their prognostic role in immune checkpoint inhibitors (ICIs) in cancer patients is still uncl
Externí odkaz:
https://doaj.org/article/2e12603b64ee4d0c8007b0cceb2b7e7d
Autor:
Yao Jin, Aili Tan, Jia Feng, Zexi Xu, Peiwei Wang, Peng Ruan, Ruijun Luo, Yiming Weng, Min Peng
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
ObjectiveThe objective of this systematic review and meta-analysis was to determine the prognostic value of memory CD8(+) T cells in cancer patients with immunotherapy.MethodsEMBASE, MEDLINE (PubMed), and Web of Science databases were searched to ide
Externí odkaz:
https://doaj.org/article/c5872561a85c477d88e113bc5ed9e6c7
Autor:
Mao Ouyang, Ethan E White, Hui Ren, Qin Guo, Ian Zhang, Hang Gao, Song Yanyan, Xuebo Chen, Yiming Weng, Anna Da Fonseca, Sunny Shah, Edwin R Manuel, Leying Zhang, Steven L Vonderfecht, Darya Alizadeh, Jacob M Berlin, Behnam Badie
Publikováno v:
PLoS ONE, Vol 11, Iss 2, p e0148139 (2016)
Even when treated with aggressive current therapies, most patients with glioblastoma survive less than two years. Rapid tumor growth, an invasive nature, and the blood-brain barrier, which limits the penetration of large molecules into the brain, all
Externí odkaz:
https://doaj.org/article/0277430924f64a69a452863fbd12d195